CONNECT MIOT
Past events at MIOT
IBHI Indo-UK HIPEC Meet at MIOT International, Chennai
IBHI organized a Indo-UK HIPEC Meet on 21st & 22nd November, 2014 at MIOT International. Taking great pleasure in announcing for the first time ever a reduce in the risk of dying from Cancer of the Abdominal wall.Previously Cancer in this area either primary or due to spread had a risk of death of 95%.Deaths of hundreds of cancer patients in India can be reduced by more than 25% by this treatment.
The normal procedure called HIPEC involves special drugs at an optimum temperature introduced into the abdomen after removal of the affected abdominal lining (peritoneum).This procedurewasdiscussed by experts from United Kingdom and India at MIOTHospitals,Chennai.
The first day involved explanation of the procedure, understanding which patients will benefit and demonstration through lectures on how the procedure should be done. The Second day involvedlive surgery to actually showcase this procedure followed by special sessions for nurses who are essential for administering cancer drugs.
Details Regarding HIPEC
HIPEC (Hyperthermic Intraoperative Peritoneal Chemotherapy), or ‘Hot Chemotherapy’ as it is commonly referred to in the medical world, is no longer science fiction. This cutting-edge treatment is today being offered by leading global centres as a definite alternative to traditional chemotherapy in select patients with advanced or complex abdominal cancers. It has brought new hope to patients across the world by dramatically improving survival periods and giving them a good quality of life.
How does it work?
Advanced or complex abdominal cancers often spread to the peritoneal lining, which does not get adequately treated by chemotherapy delivered intraveneously. This invariably results in relapses, post surgery. HIPEC treatment done immediately after surgery delivers a carefully calibrated dosage of heated chemotherapeutic drugs directly into the abdominal cavity. Gently agitated before being drained out, it destroys any microscopic cancer cells that may remain post surgery – improving its effectiveness manifold. There are only about 30 centres, world-wide, offering this treatment currently.